Stockscreener 앱 받기
4.54
0.22%
-0.010
시간 외 거래:
4.58
0.04
+0.88%
Abeona Therapeutics Inc 주식(ABEO)의 최신 뉴스
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2025 earnings call transcript - MSN
Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB - Seeking Alpha
HC Wainwright & Co. Reiterates Buy Rating for Abeona Therapeutics (ABEO) | ABEO Stock News - GuruFocus
Abeona Therapeutics (NASDAQ:ABEO) Earns Buy Rating from HC Wainwright - MarketBeat
Abeona Therapeutics (ABEO) Receives a Buy from Oppenheimer - The Globe and Mail
Abeona Therapeutics Balances Big Windfall With Slow Ramp - The Globe and Mail
Abeona Therapeutics: Early Zevaskyn Revenue Marks A Key Inflection Point (NASDAQ:ABEO) - Seeking Alpha
Abeona Therapeutics (ABEO) One Off US$152.4m Gain Tests Bullish Profitability Narrative - simplywall.st
Abeona targets activation of 7 QTCs for ZEVASKYN by end of 2026 as patient demand doubles - MSN
Stifel cuts Abeona Therapeutics stock price target on sales timing By Investing.com - Investing.com India
Oppenheimer reiterates Abeona Therapeutics stock rating at Outperform By Investing.com - Investing.com Canada
Stifel cuts Abeona Therapeutics stock price target on sales timing - Investing.com
Abeona Therapeutics Inc (ABEO) Q4 2025 Earnings Call Highlights: - GuruFocus
Abeona Therapeutics Reports 2025 Financial Results, ZEVASKYN Launch Momentum, and $191.4M Cash Position - Minichart
Abeona (ABEO) Fourth Quarter 2025 Earnings Conference Call Transcript - Bitget
ABEO: Strong launch momentum, profitability, and expanding access position ZEVASKYN for growth - TradingView
Abeona (ABEO) Q4 2025 Earnings Call Transcript - The Globe and Mail
Abeona Therapeutics Q4 Earnings Call Highlights - MarketBeat
ABEO: 2025 marked a profitable year with ZEVASKYN's launch, expanding access, and robust financials - TradingView
Earnings call transcript: Abeona Therapeutics Q4 2025 shows revenue growth - Investing.com
Abeona Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Abeona Therapeutics 2025 Financial Results: Annual Profit and Q4 BeatNews and Statistics - IndexBox
Abeona Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Abeona Therapeutics (ABEO) Reports Mixed FY Results with Revenue Beat - GuruFocus
Abeona Therapeutics FY income from operations USD -89.448 million versus Ibes estimate USD -78.4 million - marketscreener.com
Abeona Therapeutics (NASDAQ:ABEO) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
ABEO Exceeds Revenue Expectations with Strong Biopsy and Treatme - GuruFocus
ABEONA THERAPEUTICS ($ABEO) Releases Q4 2025 Earnings - Quiver Quantitative
The latest financial data released by biotechnology company Abeona Therapeutics Inc shows its annual operating income recorded at -89.448 millions USD. - Bitget
Abeona Therapeutics: Fourth Quarter Earnings Overview - Bitget
Abeona Therapeutics 10-K: $5.82M Revenue, $71.18M Net Income - TradingView
Abeona Therapeutics: Q4 Earnings Snapshot - Barchart
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates - The Manila Times
Abeona (NASDAQ: ABEO) shifts to commercial stage with ZEVASKYN and $155M PRV cash - Stock Titan
Abeona Therapeutics (Nasdaq: ABEO) turns 2025 profit on PRV sale and builds cash - Stock Titan
First ZEVASKYN patients treated as Abeona banks $191M cash - Stock Titan
Earnings Scheduled For March 17, 2026 - Benzinga
Abeona Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Abeona Therapeutics CFO Vazzano sells $3.7k in stock - Investing.com
Abeona Therapeutics CFO Vazzano sells $3.7k in stock By Investing.com - Investing.com UK
ABEO (NASDAQ) Form 144: 2,000 RSUs listed; insider sold 18,666 shares - Stock Titan
Abeona (NASDAQ: ABEO) CFO sells 785 shares to cover tax obligations - Stock Titan
Published on: 2026-03-17 00:22:57 - baoquankhu1.vn
Abeona Therapeutics Inc. $ABEO Shares Sold by Boone Capital Management LLC - MarketBeat
Abeona Therapeutics Inc. (NASDAQ:ABEO) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Understanding Momentum Shifts in (ABEO) - Stock Traders Daily
Abeona Therapeutics Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Abeona reports progress in ZEVASKYN gene therapy launch - Investing.com Nigeria
Q4 EPS Forecast for Abeona Therapeutics Increased by Analyst - MarketBeat
HC Wainwright Has Bullish Outlook for ABEO FY2025 Earnings - MarketBeat
Abeona Therapeutics (ABEO) Receives Consistent Analyst Rating of "Buy" | ABEO Stock News - GuruFocus
Abeona Therapeutics Says ZEVASKYN Launch Is Back on Track, Eyes Profitability in 2026 - MarketBeat
Abeona Therapeutics at Leerink Global Healthcare Conference: Strategic Launch Insights - Investing.com Canada
HC Wainwright Reaffirms "Buy" Rating for Abeona Therapeutics (NASDAQ:ABEO) - MarketBeat
Abeona Therapeutics (ABEO) Projected to Post Earnings on Tuesday - MarketBeat
Oppenheimer Maintains Outperform on Abeona Therapeutics (ABEO) PT $22 March 2026 - Meyka
Oppenheimer raises Abeona Therapeutics price target on launch progress By Investing.com - Investing.com Nigeria
Oppenheimer raises Abeona Therapeutics price target on launch progress - Investing.com
Why Is Abeona Therapeutics Inc. (ABEO) Stock Up Today? - Meyka
Abeona Therapeutics Announces Momentum in ZEVASKYN® Gene Therapy Launch for Recessive Dystrophic Epidermolysis Bullosa (RDEB) - Minichart
Abeona Therapeutics (ABEO) Progress with Zevaskyn Launch - GuruFocus
Abeona reports progress in ZEVASKYN gene therapy launch By Investing.com - Investing.com Canada
Abeona Accelerates ZEVASKYN Commercial Momentum and Market Access - TipRanks
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch - The Manila Times
Abeona Therapeutics reports early commercial momentum and payer coverage for ZEVASKYN launch - TradingView
1.20%
0.06%
자본화:
|
볼륨(24시간):